Russia plans to start use domestic reference materials in pharma secto

The Russian Parliament (State Duma) has said it will consider
establishing the priority of using domestic reference materials
in the pharmaceutical industry.

Currently local pharmaceutical manufacturers use such samples to
control the quality of drug batches. Now most of the players
continue to use the products of the US and European
Pharmacopoeias, imported through third countries, however there
is a possibility such a situation will change already…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source